Analyst calls: LM, FSLR, KEY, HIG, PPO, ASH, VRTX, MKL, CX ...
Posted Oct 30th 2008 11:31AM by Eric Buscemi
Filed under: Analyst upgrades and downgrades, Analyst initiations, Pan Amer Silver (PAAS), CEMEX S.A.B. de C.V. (CX)
.gif)
Analyst upgrades:
- Jefferies upgraded Legg Mason (NYSE: LM) to Buy from Hold on valuation following the recent sell-off, as they find the risk/reward attractive at current levels. However, the firm lowered their target to $23 from $44.
- Merriman raised First Solar (NASDAQ: FSLR) to Buy from Neutral after the company showed "industry leading growth" in Q3. The firm has a 12-month price target range of $185 to $195 per share.
- Ladenburg upgraded KeyCorp (NYSE: KEY) to Buy from Neutral.
- Citigroup upgraded shares of Silicon Laboratories (NASDAQ: SLAB) to Buy from Hold on valuation and expects the company to post above average industry growth in 2009.
- Janus Capital (NYSE: JNS) was upgraded to Neutral from Underweight at JP Morgan.
- Associated Estates Realty (NYSE: AEC) was upgraded to Outperform from Neutral at Baird.
Analyst downgrades:
- Merrill downgraded Hartford Financial (NYSE: HIG) to Neutral from Buy citing greater than expected capital volatility and the potential for another $2B capital raise or more in order to maintain ratings.
- Baird downgraded Polypore Inernational (NYSE: PPO) to Neutral from Outperform and lowered its target to $16 from $28 due to the company's announcement that its battery separator pact with Johnson Controls (NYSE: JCI) will end in December.
- Ashland (NYSE: ASH) and Pan American Silver (NASDAQ: PAAS) were cut to Neutral from Overweight at JP Morgan.
- Achillion (NASDAQ: ACHN) was downgraded at Oppenheimer to Perform from Outperform.
Analyst initiations:
- Merriman believes the Vertex's (NASDAQ: VRTX) lead compound, telaprevir, is the most advanced therapeutic for the treatment of hepatitis C in clinical development. The firm thinks shares are undervalued at current levels and initiated shares with a Buy rating.
- Markel (NYSE: MKL) was initiated at Keefe Bruyette with a Market Perform and $360 target. The firm believes shares are fairly valued at current levels.
- Cemex (NYSE: CX) was assumed with an Underperform rating and $7 target at Credit Suisse.
- Merriman believes Pharmasset (NASDAQ: VRUS) has a strong pipeline with drugs targeting major indications in the infectious disease space. The firm, which started shares with a Buy rating, thinks shares could trade closer to a range of $22 to $26 in the next 12 months.
Tags: achn, aec, ash, cx, fslr, hig, inthenews, jci, jns, key, lm, mkl, paas, ppo, slab, vrtx, vrus
Twitter finally reveals revenue ambition, wants to be Google -- but not yet
Google says: Chrome for Christmas
Why is gold marching higher? Ask the central bankers
